Close menu




July 23rd, 2026 | 07:50 CEST

Panic in the Multi-Billion-Dollar Market: Novo Nordisk and Halozyme Therapeutics Face Headwinds—BioNxt Solutions Nears a Turning Point

  • Biotechnology
  • Biotech
  • Pharma
  • Innovations
Photo credits: AI

The global pharmaceutical market is worth hundreds of billions of dollars. Yet one of the industry's most surprising realities is that success increasingly depends not only on the active ingredient itself but also on how it is delivered. This does not refer to the cardboard box, but to the dosage form. Whenever patents expire, and blockbuster drugs face competition, innovative biotech companies seize the opportunity. New drug delivery technologies can transform well-known substances into more effective medicines, reduce side effects, and open up entirely new treatment options for patients. While established pharmaceutical giants spend vast sums defending market exclusivity, agile second-tier biotech companies are driving innovation through next-generation drug delivery platforms.

time to read: 3 minutes | Author: Nico Popp
ISIN: Bionxt Solutions Inc. | CA0909741062 | CSE:BNXT , OTCQB: BNXTF , NOVO NORDISK A/S | DK0062498333 , HALOZYME THERAPEU.DL-_001 | US40637H1095

Table of contents:


    Novo Nordisk: Mini-Robots and Protective Shields for the Stomach

    Pharmaceutical giant Novo Nordisk relies on two extremely sophisticated technologies in its peptide therapies to outwit aggressive stomach acids. In the case of the oral semaglutide tablet Rybelsus, the co-formulated excipient salcaprozate sodium protects the sensitive peptide by neutralizing the acidic digestive enzyme pepsin and increasing the permeability of the stomach wall by 43%. With Amycretin, the company is already advancing its next promising candidate, which demonstrated significant weight loss of about 13% in initial trials. Together with MIT researchers, Novo Nordisk is even developing a mechanical injection capsule that autonomously and completely painlessly injects biologically active ingredients directly into the tissue layer of the stomach wall via a microneedle. In insulin trials, this mechanical approach achieves an astonishing bioavailability of up to 80%. This proves that smart delivery systems can make all the difference.

    Halozyme Therapeutics: Market Dominance and the Legal Battle

    With its patented ENHANZE technology, the U.S. biotech company Halozyme Therapeutics dominates the field of enzymatic tissue penetration, replacing hours-long infusions via syringe. For fiscal year 2026, Halozyme Therapeutics is targeting total revenue of up to $1.81 billion, which would represent significant growth of 30%. A recently concluded partnership secures the company revenue-based royalties in the mid-single-digit percentage range for a novel antibody used to treat severe bone marrow diseases. However, its monopoly is faltering, as South Korean competitor Alteogen is also gaining market share with its own enzyme platform. In addition, Halozyme has already suffered significant legal setbacks this year in British and U.S. patent courts, resulting in the loss of key intellectual property rights.

    BioNxt Solutions: A Breakthrough with Dissolvable Ultra-Thin Films

    In the shadow of the pharmaceutical giants, the Canadian-German biotech company BioNxt Solutions is developing innovative sublingual dissolvable films designed to revolutionize the traditional administration of medications. The main focus is on the BNT23001 program, which embeds the proven active ingredient cladribine into a special hydrophilic polymer matrix for the treatment of multiple sclerosis. Since many patients suffer from severe swallowing difficulties, the dissolvable thin film under the tongue offers significant advantages. Pharmacokinetic studies in large-animal models demonstrate that the cladribine dissolvable film achieves more than 40% higher systemic bioavailability than the conventional reference tablet, Mavenclad. This superiority allows for a lower dose, thereby sparing patients' immune systems and reducing costs. Further development of BNT23001 is progressing rapidly. Together with the Munich-based specialty laboratory Gen-Plus, BioNxt has successfully submitted clinical trial samples. BioNxt Solutions' sublingual cladribine platform is protected by European unitary patent EP4539857 in 18 EU member states. This intellectual property right is supplemented by priority applications in the US, Canada, Japan, and Australia.

    A turnaround is in the air at BioNxt.

    In addition to its flagship project, BioNxt Solutions is strategically expanding its product portfolio to target other autoimmune diseases and longevity applications. The BNT23002 program is paving the way for the use of cladribine in myasthenia gravis, an autoimmune disease that causes muscle weakness, while BNT24002 and BNT24003 target the indications of lupus nephritis (kidney inflammation) and rheumatoid arthritis (chronic inflammation of the synovial membrane). With the BNT24005 program, BioNxt Solutions aims to replace the weight-loss injection and is researching an oral semaglutide film for the obesity market that does not infringe Novo Nordisk's patents.

    BioNxt: Diversified Portfolio – Even a Single Approach Can Make a Difference

    Catalysts for future performance include clinical data and the continued development of the semaglutide dissolvable film in the multi-billion-dollar market for obesity therapies. With its various projects, BioNxt has a diversified portfolio and has several irons in the fire. The fact that developing therapies and biotechnology platforms is a challenging business is evident in the stock's share price, which has been falling for months. It seems that the patience of many market participants is wearing thin. Given a market capitalization of only around CAD 38 million, however, this could also create opportunities—if a groundbreaking study succeeds, a trend reversal is likely. Speculative investors can keep an eye on BioNxt Solutions stock.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Stefan Feulner on November 20th, 2026 | 05:55 CET

    Merck KGaA, BioNxt Solutions and Novartis – A billion-dollar market is being reshaped

    • Biotechnology

    Multiple sclerosis has long been a billion-dollar market. But as established drugs come under pressure from expiring patents, new therapeutic approaches are advancing through clinical development. The focus is not just on better active ingredients, but increasingly on easier ways of administering treatments. A German pharmaceutical group is battling generic competition, a small biotech developer is betting on a new drug delivery format, and a Swiss industry giant has reported promising Phase 3 data. This creates significant opportunities for investors, each with a different risk profile.

    Read

    Commented by Armin Schulz on November 18th, 2026 | 05:30 CET

    Pharma Turnaround Stocks Under Review: Evotec, Vidac Pharma and Novo Nordisk – Restructuring, Clinical Trial Results and Outlook

    • Evotec
    • Vidac Pharma
    • Novo Nordisk
    • Drug discovery
    • Biotech
    • Pharma
    • Cancer
    • Oncology
    • Warburg effect
    • Obesity
    • Diabetes
    • Weight-loss pill

    Between November 4 and 9, three pharma and biotech stocks released news that suggests a turning point. At one, the quarterly loss before exceptional items narrowed; at the second, initial data from a placebo-controlled trial are available; and the third has raised its full-year guidance. These are not yet proof of a lasting turnaround, but they are verifiable signs of progress. If this trajectory can be maintained, hope could soon turn into substance. We therefore take a closer look at Evotec, Vidac Pharma and Novo Nordisk to see which has turnaround potential.

    Read

    Commented by Armin Schulz on November 17th, 2026 | 19:35 CET

    Bayer, Cardiol Therapeutics, Novartis – Biotech stocks and pharmaceutical giants in the race for the heart

    • Bayer
    • Cardiol Therapeutics
    • Novartis
    • Heart disease
    • Asundexian
    • Pharma
    • Pericarditis
    • CardiolRx
    • Leqvio

    Created and Published on Behalf of Cardiol Therapeutics

    Cardiology is one of the most exciting fields in the pharmaceutical industry. Four days in Chicago have shown just how much is happening in cardiovascular medicine. From November 6 to 9, pharmaceutical giants and small biotech companies gathered at the American Heart Association Scientific Sessions annual congress with a shared goal: to improve care for patients with cardiovascular disease. The major players bring experience and capital, while smaller companies often contribute fresh ideas. When a company succeeds in securing regulatory approval, investors stand to benefit. This interplay is precisely what makes the market so interesting for investors. We therefore take a closer look at Bayer, Cardiol Therapeutics, and Novartis.

    Read